Source:http://linkedlifedata.com/resource/pubmed/id/18490714
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
2008-5-20
|
| pubmed:abstractText |
The type I IFNs exert a range of activities that include antiviral, antiproliferative, and immunomodulatory effects. To study this further, we have constructed recombinant vaccinia viruses expressing HIV or hemagglutinin (HA) Ags along with murine type I IFNs, IFN-alpha(4) (HA-VV-IFN-alpha(4)), IFN-beta (HA-VV-IFN-beta), or IFN-epsilon (HIV-VV-IFN-epsilon), a recently discovered member of this family. Our aims were to characterize IFN-epsilon functionality as a type I IFN and also to study the biological properties of these factors toward the development of safer and more effective vector-based vaccines. HIV-VV-IFN-epsilon and HA-VV-IFN-beta grew to lower titers than did their parental controls in murine cell lines. In vivo, however, HIV-VV-IFN-epsilon growth was not attenuated, while IFN-beta demonstrated potent local antiviral activity with no replication of HA-VV-IFN-beta detected. Flow cytofluorometric analysis of B lymphocytes incubated with virally encoded IFN-epsilon showed up-regulation of activation markers CD69 and CD86, while RT-PCR of IFN-epsilon-treated cells revealed that gene expression levels of antiviral proteins were elevated, indicating the induction of an antiviral state. The use of these constructs in a poxvirus prime-boost immunization regime led to robust humoral and cellular immune responses against the encoded Ags, despite the lack of replication in the case of HA-VV-IFN-beta. Thus, coexpression of these factors may be beneficial in the design of safer vector-based vaccines. Our data also indicate that while IFN-epsilon exhibits certain biological traits similar to other type I IFNs, it may also have a specific role in mucosal immune regulation that is quite distinct.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Hemagglutinin Glycoproteins...,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon Type I,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-beta,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Vaccines
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0022-1767
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
180
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
7158-66
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:18490714-Animals,
pubmed-meshheading:18490714-Cell Line,
pubmed-meshheading:18490714-Ectromelia, Infectious,
pubmed-meshheading:18490714-Ectromelia virus,
pubmed-meshheading:18490714-Female,
pubmed-meshheading:18490714-Genetic Vectors,
pubmed-meshheading:18490714-HIV,
pubmed-meshheading:18490714-Hemagglutinin Glycoproteins, Influenza Virus,
pubmed-meshheading:18490714-Immunization, Secondary,
pubmed-meshheading:18490714-Interferon Type I,
pubmed-meshheading:18490714-Interferon-alpha,
pubmed-meshheading:18490714-Interferon-beta,
pubmed-meshheading:18490714-Mice,
pubmed-meshheading:18490714-Mice, Inbred BALB C,
pubmed-meshheading:18490714-Mice, Knockout,
pubmed-meshheading:18490714-Mice, Nude,
pubmed-meshheading:18490714-Up-Regulation,
pubmed-meshheading:18490714-Vaccinia,
pubmed-meshheading:18490714-Vaccinia virus,
pubmed-meshheading:18490714-Viral Vaccines
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy.
|
| pubmed:affiliation |
Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia. stephanie@anu.edu.au
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|